Do Anti-Inflammatory Drugs Prevent Repeat Heart Events?

Inflammation helps drive coronary artery disease, but anti-inflammatory drugs do not reliably prevent repeat heart events when treated as one therapeutic class. A 2025 meta-analysis of 25 randomized controlled trials in people with established coronary heart disease found a pooled relative risk of 0.92 for major adverse cardiovascular events. The 95% confidence interval crossed 1.0, so the result was not statistically significant. The estimate leaves room for benefit, but it does not establish that newer immunomodulatory drugs broadly reduce recurrent events.

That distinction matters because "inflammation" is a biological process, not a drug mechanism. Lowering one inflammatory signal, blocking another, or broadly suppressing immune activity can produce very different clinical results. The evidence supports coronary inflammation as a residual-risk pathway worth targeting. It does not support taking an anti-inflammatory drug simply because inflammation appears somewhere on its label.

The inflammation hypothesis remains credible. The claim that anti-inflammatory drugs work as a single class does not.

Why inflammation remains a serious target

Atherosclerotic plaques are not inert plumbing deposits. They contain immune cells and inflammatory signals that can contribute to plaque formation, growth, and instability. A 2026 review of coronary inflammation describes inflammation as a driver of plaque initiation, progression, and destabilization. It also notes that high-sensitivity C-reactive protein is the most widely used systemic inflammatory biomarker, although it lacks specificity.

That biology gives researchers a sound reason to test anti-inflammatory treatments in people who already have coronary disease. It does not prove that reducing an inflammatory biomarker will prevent myocardial infarction, stroke, or cardiovascular death. Biomarkers measure biology; patients care about events. The two sometimes travel together, but they are not interchangeable.

Secondary prevention already rests on therapies with established roles, including lipid lowering, antiplatelet treatment when indicated, blood-pressure control, smoking cessation, physical activity, and cardiac rehabilitation. Inflammation-targeted treatment, where appropriate, would be an add-on to that foundation rather than a substitute for it.

The pooled result: a small estimate with too much uncertainty

The 2025 meta-analysis pooled 25 randomized trials of newer immunomodulatory drugs in established coronary heart disease. Randomization makes this the strongest type of evidence in the group for testing whether treatment changes clinical outcomes. Yet pooling trials only helps when the trials ask sufficiently similar questions. Here, the interventions targeted different inflammatory pathways, and several had neutral or failed results.

The pooled major adverse cardiovascular event result was a relative risk of 0.92, with a 95% confidence interval that crossed the no-effect value of 1.0. In practical terms, the average estimate pointed toward fewer events, but chance remained a plausible explanation. The publication therefore cannot support a confident claim of class-wide benefit.

The analysis also reported a subgroup signal only in studies with more than six months of follow-up. That finding is biologically plausible: preventing recurrent coronary events may require sustained treatment rather than a short course. Still, it is a subgroup result, not proof that duration alone determines success. Differences in drug target, patient population, trial design, and event timing may also contribute.

Why a class-wide average can mislead

A pooled estimate can hide meaningful differences between treatments. The 2025 review of anti-inflammatory strategies after acute coronary syndromes reaches a more useful clinical conclusion: low-dose colchicine has the strongest evidence base in post-myocardial infarction and chronic coronary disease, while other approaches have produced mixed results.

The same review describes interleukin-1 beta inhibition as proof of concept. It reports that interleukin-6 pathway treatments lower biomarkers, but outcome confirmation remains pending. By contrast, methotrexate, lipoprotein-associated phospholipase A2 inhibition, and p38 MAPK inhibition have not produced a universal event-reduction pattern. These are not minor technical differences. They are the reason "anti-inflammatory therapy" is too broad to function as a clinical conclusion.

Colchicine has the clearest signal, with limits

Colchicine is the most supported anti-inflammatory strategy in this evidence base, particularly after myocardial infarction and in chronic coronary disease. The parent COLCOT randomized trial enrolled 4,745 patients within 30 days after myocardial infarction and compared colchicine 0.5 mg per day with placebo. Over a median 23 months, colchicine reduced the primary ischemic composite by 23%, according to the quantitative background reported in a 2022 COLCOT pharmacogenomics analysis.

That is evidence for a specific drug, dose, population, comparator, and composite endpoint. It is not evidence that every anti-inflammatory drug will work, nor does it tell us the absolute number of events prevented because that figure is not reported here. Relative reductions can sound larger than their day-to-day clinical impact when baseline risk is low; absolute risk determines how many people need treatment to prevent one event.

The pharmacogenomics analysis adds another caution. It indicates that colchicine efficacy and safety may differ among individuals. Such findings can help explain variation in response, but they do not establish which patient should receive treatment without further validation. Genetics may refine a strategy; it does not turn an exploratory signal into a prescribing rule.

A 2025 exploratory LoDoCo2 substudy examined colchicine and changes in clonal hematopoiesis over time in chronic coronary disease. It supports questions about the long-term biology of colchicine and its interaction with inflammatory pathways. As an exploratory substudy, however, it cannot establish a new treatment standard or explain the outcome benefit on its own. Mechanistic plausibility is useful, but hard clinical endpoints carry more weight.

What the conflicting trials actually say

The mixed record does not refute the role of inflammation in coronary disease. It refutes the shortcut that any reduction in inflammation should reduce events. Different drugs act at different points in immune signaling, and broad suppression can miss the relevant pathway or introduce harms that offset benefit. Trials also differ in follow-up duration, patient risk, disease stage, endpoints, and the background treatments participants receive.

The meta-analysis has its own limitations. Combining divergent mechanisms can dilute a real benefit from one successful pathway while making the entire field look more consistent than it is. Its overall estimate was modest and statistically uncertain. The follow-up subgroup result also means that duration changes interpretation. A short trial may miss a delayed effect, but longer follow-up alone cannot rescue an ineffective mechanism.

Reviews help place these trials in context, but they cannot replace direct review of each trial's endpoint definitions, event adjudication, and risk of bias. Likewise, biomarker studies and exploratory genetic analyses can generate good hypotheses without settling whether a treatment prevents heart attacks or cardiovascular death.

Do lifestyle inflammation targets change the answer?

Some researchers are testing ways to reduce inflammatory burden outside direct cytokine or immune-pathway drugs. For example, a 2022 randomized pilot-trial protocol proposed testing periodontal treatment alone or with colchicine in 60 people with moderate-to-severe periodontitis, coronary artery disease, and high-sensitivity C-reactive protein above 2 mg/L. Its planned endpoint was inflammation at eight weeks. Because this publication is a protocol, it reports a planned study, not an outcome. Even a reduction in inflammatory markers would not by itself demonstrate fewer recurrent cardiac events.

That example illustrates the larger evidence rule: a plausible route to lower inflammation deserves testing, but patient-important outcomes decide whether it belongs in secondary prevention.

The practical verdict

For people with coronary disease, residual inflammatory risk is real, and pathway-specific treatment may help selected patients. The present evidence does not justify broad use of "next-generation anti-inflammatory drugs" as a category to prevent recurrent cardiac events. Low-dose colchicine has the strongest clinical evidence in post-myocardial infarction and chronic coronary disease; several other anti-inflammatory approaches have not replicated that result.

This is a clinician-level decision, especially for people already taking multiple cardiovascular drugs or managing other medical conditions. The rational question is not, "How do I suppress inflammation?" It is whether a specific treatment has shown that it improves outcomes for a patient with a similar clinical profile, on top of standard secondary prevention.